Jpmorgan Chase & CO Akero Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 488,046 shares of AKRO stock, worth $15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

488,046

Previous 542,267 10.0%

Holding current value

$15 Million

Previous $12.7 Million 10.07%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$21.45 - $29.34 $1.16 Million - $1.59 Million	-54,221 Reduced 10.0%	488,046 $14 Million
Q2 2024 Aug 12, 2024	BUY	$18.31 - $24.62 $3.97 Million - $5.34 Million	216,868 Added 66.65%	542,267 $12.7 Million
Q1 2024 May 10, 2024	BUY	$17.76 - $31.18 $3.06 Million - $5.38 Million	172,521 Added 112.85%	325,399 $8.22 Million
Q4 2023 Feb 12, 2024	SELL	$11.38 - $50.33 $6.39 Million - $28.3 Million	-561,700 Reduced 78.61%	152,878 $3.57 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $15.5 Million - $19.7 Million	377,258 Added 111.84%	714,578 $36.1 Million
Q2 2023 Aug 11, 2023	BUY	$36.89 - $56.88 $4.64 Million - $7.16 Million	125,852 Added 59.51%	337,320 $15.7 Million
Q1 2023 May 18, 2023	BUY	$37.27 - $50.24 $995,332 - $1.34 Million	26,706 Added 14.45%	211,468 $8.09 Million
Q1 2023 May 11, 2023	BUY	$37.27 - $50.24 $53,929 - $72,697	1,447 Added 0.79%	184,762 $7.07 Million
Q4 2022 Feb 13, 2023	SELL	$33.44 - $54.8 $1.75 Million - $2.86 Million	-52,214 Reduced 22.17%	183,315 $10 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $7,125 - $23,903	702 Added 0.3%	235,529 $8.02 Million
Q2 2022 Aug 11, 2022	BUY	$8.0 - $15.01 $1.51 Million - $2.84 Million	188,960 Added 411.97%	234,827 $2.22 Million
Q1 2022 May 11, 2022	SELL	$12.97 - $22.26 $25,382 - $43,562	-1,957 Reduced 4.09%	45,867 $651,000
Q4 2021 Feb 10, 2022	SELL	$19.87 - $26.24 $19,989 - $26,397	-1,006 Reduced 2.06%	47,824 $1.01 Million
Q3 2021 Nov 12, 2021	BUY	$18.65 - $25.46 $910,679 - $1.24 Million	48,830 New	48,830 $1.09 Million

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.42B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Akero Therapeutics, Inc. Transaction History